About the Company
Jeffery Alan Smisek (born August 17, 1954) is an American businessman, who is the president of GOOSE Capital and on the board of directors of Finch Therapeutics. Smisek previously worked in the airline industry as the chairman, president, and chief executive officer (CEO) of Continental Airlines and, later, of United Airlines.
Exchange
OTC
Fundamental Data and Insider Transactions (Quarterly data) Full Screen
Loading the fundamentals chart...
Latest News on Finch Therapeutics Group, Inc.
Here's What Finch Therapeutics Group, Inc.'s (NASDAQ:FNCH) Shareholder ...
Finch Therapeutics Group is not a large company by global standards. It has a market capitalization of US$450m, which means it wouldn't have the attention of many institutional investors.
Bullish Finch Therapeutics Group, Inc. (NASDAQ:FNCH) investors are yet ...
Insiders who acquired US$42m worth of Finch Therapeutics Group, Inc.'s (NASDAQ:FNCH) stock at an average price of US$17.00 in the past 12 months may be dismayed by the recent 8.7% price decline ...
As Finch Therapeutics Group, Inc. (NASDAQ:FNCH) drops to US$103m market ...
Insiders who acquired US$650k worth of Finch Therapeutics Group, Inc.'s (NASDAQ:FNCH) stock at an average price of US$10.18 in the past 12 months may be dismayed by the recent 14% price decline.
Shareholders in Finch Therapeutics Group (NASDAQ:FNCH) are in the red ...
Finch Therapeutics Group grew its revenue by 134% over the last year. That's well above most other pre-profit companies. So on the face of it we're really surprised to see the share price down 74% ...
Finch Therapeutics Reports First Quarter 2023 Financial Results and ...
SOMERVILLE, Mass., May 10, 2023 (GLOBE NEWSWIRE) -- Finch Therapeutics Group, Inc. (FNCH), a microbiome technology company with a portfolio of intellectual property and microbiome assets, today ...
Finch Therapeutics Group, Inc.: Finch Announces Delisting from Nasdaq ...
BOSTON, Oct. 21, 2024 (GLOBE NEWSWIRE) -- Finch Therapeutics Group, Inc. (Nasdaq: FNCH) ("Finch" or the "Company"), a microbiome technology company with a portfolio of intellectual property and ...
Finch Therapeutics Group Inc News (FNCH) - Investing.com
Investing.com - Finch Therapeutics Group (NASDAQ: FNCH) reported first quarter EPS of $-0.56, $0.15 worse than the analyst estimate of $-0.41. Revenue for the quarter came in at... ByInvesting.com ...
Finch Therapeutics Group Raises $36 Million in Series B Financing
SOMERVILLE, Mass.--(BUSINESS WIRE)--Finch Therapeutics Group, Inc. (Finch), a privately held microbiome therapeutics company, announced today the successful close of an oversubscribed $36 million ...
Finch Therapeutics Announces Appointment of Dr. Jo Viney and Domenic ...
SOMERVILLE, Mass.--(BUSINESS WIRE)--Finch Therapeutics Group, Inc., a clinical-stage microbiome therapeutics company, announced today the appointment of Dr. Jo Viney and Domenic Ferrante to its ...
Finch Therapeutics Group Inc (FNCH-Q) Quote - Press Release
SOMERVILLE, Mass., June 28, 2021 (GLOBE NEWSWIRE) -- Finch Therapeutics Group, Inc. (“Finch” or “Finch Therapeutics”) (Nasdaq: FNCH), a clinical-stage microbiome therapeutics company ...
Finch Therapeutics Group Inc News (FNCH) - Investing.com
ByInvesting.com •Nov 10, 2022 Finch Therapeutics Group Inc. receives Investment Bank Analyst Rating Update ByInvesting.com •Aug 09, 2022 ...
Finch Therapeutics Group Inc (FNCH) Quote - Press Release
SOMERVILLE, Mass., Sept. 08, 2021 (GLOBE NEWSWIRE) -- Finch Therapeutics Group, Inc. (“Finch” or “Finch Therapeutics”) (Nasdaq: FNCH), a clinical-stage microbiome therapeutics company ...
Similar Companies
Loading the latest forecasts...